7,840 Shares in Sanofi (NASDAQ:SNY) Acquired by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE acquired a new stake in Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,840 shares of the company’s stock, valued at approximately $378,000.

Several other large investors have also recently added to or reduced their stakes in SNY. Raymond James Financial Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $135,933,000. Boston Partners increased its stake in Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares during the period. Magnetar Financial LLC raised its holdings in Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after acquiring an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC lifted its position in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock worth $93,774,000 after purchasing an additional 514,542 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 1.7 %

SNY stock opened at $55.82 on Friday. The stock has a market capitalization of $141.66 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $55.13 and a 200-day moving average price of $52.79. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SNY shares. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.